Global Glial Cell Line Derived Neurotrophic Factor Market Research Report 2023

Publication ID:

PB503239585

Publication Date:

March 23, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Glial Cell Line Derived Neurotrophic Factor market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Glial Cell Line Derived Neurotrophic Factor in Amyotrophic Lateral Sclerosis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Glial Cell Line Derived Neurotrophic Factor include GlaxoSmithKline Plc, Treeway BV and UniQure NV, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glial Cell Line Derived Neurotrophic Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glial Cell Line Derived Neurotrophic Factor.
The Glial Cell Line Derived Neurotrophic Factor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Glial Cell Line Derived Neurotrophic Factor market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glial Cell Line Derived Neurotrophic Factor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GlaxoSmithKline Plc
Treeway BV
UniQure NV
Segment by Type
GSK-812
LAUR-301
TW-002
AMT-090
Others
Segment by Application
Amyotrophic Lateral Sclerosis
Brain Ischemia
Parkinson's Disease
Retinal Degeneration
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glial Cell Line Derived Neurotrophic Factor companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 GSK-812
1.2.3 LAUR-301
1.2.4 TW-002
1.2.5 AMT-090
1.2.6 Others
1.3 Market by Application
1.3.1 Global Glial Cell Line Derived Neurotrophic Factor Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Amyotrophic Lateral Sclerosis
1.3.3 Brain Ischemia
1.3.4 Parkinson's Disease
1.3.5 Retinal Degeneration
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Perspective (2018-2029)
2.2 Glial Cell Line Derived Neurotrophic Factor Growth Trends by Region
2.2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Glial Cell Line Derived Neurotrophic Factor Historic Market Size by Region (2018-2023)
2.2.3 Glial Cell Line Derived Neurotrophic Factor Forecasted Market Size by Region (2024-2029)
2.3 Glial Cell Line Derived Neurotrophic Factor Market Dynamics
2.3.1 Glial Cell Line Derived Neurotrophic Factor Industry Trends
2.3.2 Glial Cell Line Derived Neurotrophic Factor Market Drivers
2.3.3 Glial Cell Line Derived Neurotrophic Factor Market Challenges
2.3.4 Glial Cell Line Derived Neurotrophic Factor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glial Cell Line Derived Neurotrophic Factor Players by Revenue
3.1.1 Global Top Glial Cell Line Derived Neurotrophic Factor Players by Revenue (2018-2023)
3.1.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Players (2018-2023)
3.2 Global Glial Cell Line Derived Neurotrophic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glial Cell Line Derived Neurotrophic Factor Revenue
3.4 Global Glial Cell Line Derived Neurotrophic Factor Market Concentration Ratio
3.4.1 Global Glial Cell Line Derived Neurotrophic Factor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glial Cell Line Derived Neurotrophic Factor Revenue in 2022
3.5 Glial Cell Line Derived Neurotrophic Factor Key Players Head office and Area Served
3.6 Key Players Glial Cell Line Derived Neurotrophic Factor Product Solution and Service
3.7 Date of Enter into Glial Cell Line Derived Neurotrophic Factor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glial Cell Line Derived Neurotrophic Factor Breakdown Data by Type
4.1 Global Glial Cell Line Derived Neurotrophic Factor Historic Market Size by Type (2018-2023)
4.2 Global Glial Cell Line Derived Neurotrophic Factor Forecasted Market Size by Type (2024-2029)
5 Glial Cell Line Derived Neurotrophic Factor Breakdown Data by Application
5.1 Global Glial Cell Line Derived Neurotrophic Factor Historic Market Size by Application (2018-2023)
5.2 Global Glial Cell Line Derived Neurotrophic Factor Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Glial Cell Line Derived Neurotrophic Factor Market Size (2018-2029)
6.2 North America Glial Cell Line Derived Neurotrophic Factor Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2018-2023)
6.4 North America Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glial Cell Line Derived Neurotrophic Factor Market Size (2018-2029)
7.2 Europe Glial Cell Line Derived Neurotrophic Factor Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2018-2023)
7.4 Europe Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Market Size (2018-2029)
8.2 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2018-2023)
8.4 Asia-Pacific Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glial Cell Line Derived Neurotrophic Factor Market Size (2018-2029)
9.2 Latin America Glial Cell Line Derived Neurotrophic Factor Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2018-2023)
9.4 Latin America Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size (2018-2029)
10.2 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2018-2023)
10.4 Middle East & Africa Glial Cell Line Derived Neurotrophic Factor Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline Plc
11.1.1 GlaxoSmithKline Plc Company Detail
11.1.2 GlaxoSmithKline Plc Business Overview
11.1.3 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Introduction
11.1.4 GlaxoSmithKline Plc Revenue in Glial Cell Line Derived Neurotrophic Factor Business (2018-2023)
11.1.5 GlaxoSmithKline Plc Recent Development
11.2 Treeway BV
11.2.1 Treeway BV Company Detail
11.2.2 Treeway BV Business Overview
11.2.3 Treeway BV Glial Cell Line Derived Neurotrophic Factor Introduction
11.2.4 Treeway BV Revenue in Glial Cell Line Derived Neurotrophic Factor Business (2018-2023)
11.2.5 Treeway BV Recent Development
11.3 UniQure NV
11.3.1 UniQure NV Company Detail
11.3.2 UniQure NV Business Overview
11.3.3 UniQure NV Glial Cell Line Derived Neurotrophic Factor Introduction
11.3.4 UniQure NV Revenue in Glial Cell Line Derived Neurotrophic Factor Business (2018-2023)
11.3.5 UniQure NV Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

GlaxoSmithKline Plc
Treeway BV
UniQure NV

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂